DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

ZBH·Zimmer Biomet Holdings, Inc.

$.
-. (-.%)
High
$93.80
Open
$91.71
Market Cap
18.03B
52W High
$108.29
Low
$88.58
P. Close
$94.08
P/E
23.70
52W Low
$79.12
Fwd P/E
10.47
DailyIQ Est.
$98.22
Technical Score (1D)
59
BUY
News Sentiment
54
MIXED
Zimmer Biomet has just named Chintan Desai as President of its Asia Pacific Region, a move that signals a renewed focus on accelerating growth in one of its largest markets. Desai’s background in orthopedic implant development and sales is expected to sharpen the company’s competitive positioning and could translate into higher market share in APAC over the next few weeks. The leadership change comes amid a broader industry push for regional expansion, and investors will be watching early quarterly results for evidence of any uptick in APAC revenue. Earlier this week, speculation that Conmed is exploring a sale has added a layer of optimism to ZBH’s valuation, as a potential transaction could unlock value for the company’s portfolio. The Conmed rumor has already pushed ZBH shares toward breakout territory, indicating that market participants are pricing in a possible upside if a deal materializes. For the next 1–10 trading days, the key market implication is that ZBH’s valuation could be more sensitive to both the pace of APAC growth and the progress of Conmed’s sale negotiations. Traders should watch for any official confirmation of Conmed’s sale status, as a definitive deal announcement would likely solidify the current bullish sentiment. Simultaneously, early APAC sales data and any new product launches under Desai’s leadership will be critical to gauge whether the regional strategy is delivering tangible results. Monitoring regulatory approvals in key APAC markets and any shifts in the competitive landscape will also help determine if the leadership change translates into sustained performance gains.
Earnings Summary
Zimmer Biomet Holdings is a global medical technology firm that designs, produces, and distributes orthopedic and related medical devices, with a focus on knee and hip reconstructive products, sports medicine, trauma, and craniomaxillofacial solutions, and it also develops surgical robotics to enhance implant precision. In the last two quarters with actual results, Q4 2025 revenue rose to $2.2438 billion from $2.0014 billion in Q3 2025, a 12.1% increase, while EPS climbed from $1.90 to $2.42, a 27% jump; the preceding two quarters showed a mixed picture, with Q2 2025 revenue up 8.6% from Q1 2025 but Q3 2025 revenue falling 3.7% from Q2 2025, and EPS moving from $1.81 to $2.07 in Q2 2025 before declining to $1.90 in Q3 2025. Across five consecutive quarters, Zimmer Biomet has consistently beat earnings estimates, with EPS exceeding forecasts in Q4 2024, Q1 2025, Q2 2025, Q3 2025, and Q4 2025, and revenue beating the single available estimate in Q4 2025. Year‑over‑year, Q4 2025 revenue grew 10.7% and EPS grew 4.7% versus Q4 2024, underscoring a steady upward trajectory in top‑line and profitability despite the quarterly volatility. Recent news highlights a strategic leadership shift in the Asia Pacific region, with Chintan Desai’s appointment expected to accelerate growth in a key market, and speculation that Conmed may be exploring a sale, both of which could influence valuation and market share; the company’s upcoming earnings call on August 5 will provide management commentary on revenue, operating margins, and forward guidance, while BMO’s recent rating notes steady revenue growth and potential margin improvement from new knee‑joint and robotic‑surgery products, though regulatory approvals remain a key uncertainty. Investors should watch for early APAC revenue data, any confirmation of a Conmed transaction, updates on robotic‑surgery regulatory approvals, and management’s discussion of cost controls and margin targets in the next earnings release, as these factors will shape the company’s near‑term earnings momentum and valuation outlook.

EPS

EstBeatMiss
$1.67$1.88$2.09$2.31$2.52Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$2.01 - -
Q4'25$1.91$2.42+26.8%
Q3'25$1.87$1.90+1.8%
Q2'25$1.98$2.07+4.8%
Q1'25$1.77$1.81+2.3%
Q4'24$2.29$2.31+0.8%

Revenue

EstBeatMiss
$1.9B$2.0B$2.1B$2.2B$2.3BQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$2.1B - -
Q4'25$2.1B$2.2B+9.0%
Q3'25 - $2.0B -
Q2'25 - $2.1B -
Q1'25 - $1.9B -
Q4'24 - $2.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ZBH Stock Snapshot

ZBH is currently trading at $90.58, giving Zimmer Biomet Holdings, Inc. a market cap of 18.03B and a P/E ratio of 23.7. Today's range spans $88.58–$93.80, with shares opening at $91.71 and moving down $3.50 (3.7%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 54/100.

Over the past year ZBH has traded between $79.12 and $108.29 - the current price is +14.5% off the 52-week low and -16.4% from the high. 35 analysts cover the stock with a Hold consensus and a mean 12-month target of $98.05 (range $83.00–$130.00), implying upside of +8.2%.

ZBH is in consolidation mode: 59/100 technical score (HOLD), neutral sentiment at 54/100, price at $90.58 (in the lower half of its 52-week range within $79.12–$108.29). The current P/E ratio stands at 23.7. The 18.03B market cap in Healthcare means the stock is widely covered and any shift in analyst sentiment or earnings expectations will be immediately reflected in price - making the current neutral phase a good time to track upcoming catalysts closely.

In neutral phases, large-cap Healthcare names like ZBH are often where sector rotation debates play out quietly — at 18.03B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 59/100 (HOLD) and neutral sentiment (54/100) at $90.58 (in the lower half of its 52-week range) describe a stock that is being considered rather than avoided.